{"filing":{"accession_number":"0001104659-26-067474","cik":"0001137883","ticker":"BCLI","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","form":"8-K","filing_date":"2026-05-28","report_date":null,"primary_document":"tm2615772d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926067474/tm2615772d1_8k.htm"},"events":[{"id":8360,"run_id":7341,"accession_number":"0001104659-26-067474","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Peter Pitts was appointed as a director of Brainstorm Cell Therapeutics effective May 25, 2026, expanding the Board from seven to eight directors. The appointment was approved by the Board and disclosed via press release on May 28, 2026.","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","filing_date":"2026-05-28","form":"8-K","submitted_at":null,"items":[{"id":2216,"accession_number":"0001104659-26-067474","item_number":"5.02","item_title":"Departure of Directors or Principal Officers; Election","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Peter Pitts as a director of Brainstorm Cell Therapeutics, effective May 25, 2026, following Board approval to expand the Board from seven to eight directors. While the disclosure includes equity compensation details (a 150,000-share option grant), the principal disclosed action is Pitts taking a director role, making this an exec_appointment rather than exec_compensation. The appointment of an independent director with substantial healthcare policy experience is material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:15:21.753806+00:00","company_name":"","ticker":null,"filing_date":""},{"id":2217,"accession_number":"0001104659-26-067474","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses Mr. Pitts' appointment to the Board of Directors via press release dated May 28, 2026. Board appointments are material events affecting the composition and governance of the registrant. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 5.02, the substance is clearly an executive/director appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:15:21.753806+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2216,"accession_number":"0001104659-26-067474","item_number":"5.02","item_title":"Departure of Directors or Principal Officers; Election","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Peter Pitts as a director of Brainstorm Cell Therapeutics, effective May 25, 2026, following Board approval to expand the Board from seven to eight directors. While the disclosure includes equity compensation details (a 150,000-share option grant), the principal disclosed action is Pitts taking a director role, making this an exec_appointment rather than exec_compensation. The appointment of an independent director with substantial healthcare policy experience is material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:15:21.753806+00:00","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","filing_date":"2026-05-28"},{"id":2217,"accession_number":"0001104659-26-067474","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses Mr. Pitts' appointment to the Board of Directors via press release dated May 28, 2026. Board appointments are material events affecting the composition and governance of the registrant. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 5.02, the substance is clearly an executive/director appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:15:21.753806+00:00","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","ticker":"BCLI","filing_date":"2026-05-28"}]}